SLC5A2 and heart failure: While both classes have been shown to significantly reducecardiovascular risk in various randomized controlled trials, direct comparative evidence in real-world clinical settings remains limited.Our findings suggest that SGLT2 inhibitors may offer a marginally superior protective effect against major adverse cardiovascular events(MACE), particularly in reducing heart failure-related hospitalizations, while both drug classes demonstrated comparable efficacy inglycemic control.